News Briefs: Share of Highly Rated MA-PD Plans Will Drop in 2023
On Oct. 7, CMS released the 2023 Medicare Advantage Star Ratings, revealing that 51.3% of Medicare Advantage Prescription Drug (MA-PD) plan contracts will be rated 4 stars and above next year. That’s down from 68.4% of 2022 MA-PD contracts, Citi analyst Jason Cassorla observed in a note to investors. On an enrollment basis, 72.1% of current MA-PD enrollees are in plans rated 4 stars and above for 2023, down from 89.7% in 2022. “The lower MA Star Ratings for 2023 on a [year-over-year] basis are largely a function of CMS removing many of the COVID-19-related guardrails and relaxed criteria that aided Stars performance for 2021-2022,” Cassorla pointed out. “Ratings for 2023 were also impacted by changes to how plans are rated with CMS a greater emphasis on the Consumer Assessment of Healthcare Providers and Systems survey.”
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile